Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation.

Golay J, Valgardsdottir R, Musaraj G, Giupponi D, Spinelli O, Introna M.

Blood. 2019 Mar 28;133(13):1395-1405. doi: 10.1182/blood-2018-07-864538. Epub 2019 Jan 17.

2.

Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumors.

Golay J, Martinelli S, Alzani R, Cribioli S, Albanese C, Gotti E, Pasini B, Mazzanti B, Saccardi R, Rambaldi A, Introna M.

Cytotherapy. 2018 Aug;20(8):1077-1088. doi: 10.1016/j.jcyt.2018.06.003. Epub 2018 Aug 7.

PMID:
30093325
3.

Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: Best practices and clinical significance.

Golay J, Pedrini O, Capelli C, Gotti E, Borleri G, Magri M, Vailati F, Passera M, Farina C, Rambaldi A, Introna M.

Cytotherapy. 2018 Feb;20(2):262-270. doi: 10.1016/j.jcyt.2017.11.009. Epub 2017 Dec 12.

PMID:
29246649
4.

Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation.

Introna M, Lussana F, Algarotti A, Gotti E, Valgardsdottir R, Micò C, Grassi A, Pavoni C, Ferrari ML, Delaini F, Todisco E, Cavattoni I, Deola S, Biagi E, Balduzzi A, Rovelli A, Parma M, Napolitano S, Sgroi G, Marrocco E, Perseghin P, Belotti D, Cabiati B, Gaipa G, Golay J, Biondi A, Rambaldi A.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2070-2078. doi: 10.1016/j.bbmt.2017.07.005. Epub 2017 Jul 13.

5.

Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?

Golay J.

J Autoimmun. 2017 Dec;85:6-19. doi: 10.1016/j.jaut.2017.06.002. Epub 2017 Jun 27. Review.

PMID:
28666691
6.

The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies.

Golay J, Ubiali G, Introna M.

Haematologica. 2017 Oct;102(10):e400-e403. doi: 10.3324/haematol.2017.169334. Epub 2017 Jun 22. No abstract available.

7.

Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies.

Valgardsdottir R, Cattaneo I, Klein C, Introna M, Figliuzzi M, Golay J.

Blood. 2017 May 11;129(19):2636-2644. doi: 10.1182/blood-2016-08-735605. Epub 2017 Mar 13.

8.

Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories.

Gaipa G, Introna M, Golay J, Nolli ML, Vallanti G, Parati E, Giordano R, Romagnoli L, Melazzini M, Biondi A, Biagi E.

Cytotherapy. 2016 Apr;18(4):481-6. doi: 10.1016/j.jcyt.2016.01.002.

PMID:
26971677
9.

Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.

Golay J, Choblet S, Iwaszkiewicz J, Cérutti P, Ozil A, Loisel S, Pugnière M, Ubiali G, Zoete V, Michielin O, Berthou C, Kadouche J, Mach JP, Duonor-Cérutti M.

J Immunol. 2016 Apr 1;196(7):3199-211. doi: 10.4049/jimmunol.1501592. Epub 2016 Feb 26.

10.

Thermoregulation and microhabitat choice in the polymorphic asp viper (Vipera aspis).

Muri D, Schuerch J, Trim N, Golay J, Baillifard A, El Taher A, Dubey S.

J Therm Biol. 2015 Oct;53:107-12. doi: 10.1016/j.jtherbio.2015.06.009. Epub 2015 Jul 2.

PMID:
26590462
11.

Clinical grade expansion of MSCs.

Capelli C, Pedrini O, Valgardsdottir R, Da Roit F, Golay J, Introna M.

Immunol Lett. 2015 Dec;168(2):222-7. doi: 10.1016/j.imlet.2015.06.006. Epub 2015 Jun 17.

PMID:
26092523
12.

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.

Da Roit F, Engelberts PJ, Taylor RP, Breij EC, Gritti G, Rambaldi A, Introna M, Parren PW, Beurskens FJ, Golay J.

Haematologica. 2015 Jan;100(1):77-86. doi: 10.3324/haematol.2014.107011. Epub 2014 Oct 24.

13.

A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy.

Golay J, D'Amico A, Borleri G, Bonzi M, Valgardsdottir R, Alzani R, Cribioli S, Albanese C, Pesenti E, Finazzi MC, Quaresmini G, Nagorsen D, Introna M, Rambaldi A.

J Immunol. 2014 Nov 1;193(9):4739-47. doi: 10.4049/jimmunol.1401550. Epub 2014 Sep 29.

14.

Direct involvement of CD56 in cytokine-induced killer-mediated lysis of CD56+ hematopoietic target cells.

Valgardsdottir R, Capitanio C, Texido G, Pende D, Cantoni C, Pesenti E, Rambaldi A, Golay J, Introna M.

Exp Hematol. 2014 Dec;42(12):1013-21.e1. doi: 10.1016/j.exphem.2014.08.005. Epub 2014 Sep 6.

PMID:
25201755
15.

Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols.

Capelli C, Pedrini O, Cassina G, Spinelli O, Salmoiraghi S, Golay J, Rambaldi A, Giussani U, Introna M.

Haematologica. 2014 Jun;99(6):e94-7. doi: 10.3324/haematol.2014.104711. Epub 2014 Mar 28. No abstract available.

16.

Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients.

Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, Longoni D, Pavan F, Masciocchi F, Algarotti A, Micò C, Grassi A, Deola S, Cavattoni I, Gaipa G, Belotti D, Perseghin P, Parma M, Pogliani E, Golay J, Pedrini O, Capelli C, Cortelazzo S, D'Amico G, Biondi A, Rambaldi A, Biagi E.

Biol Blood Marrow Transplant. 2014 Mar;20(3):375-81. doi: 10.1016/j.bbmt.2013.11.033. Epub 2013 Dec 7.

17.

Comment on "Reduced T-dependent humoral immunity in CD20-deficient mice".

Golay J.

J Immunol. 2013 Dec 15;191(12):5783. doi: 10.4049/jimmunol.1390065. No abstract available.

18.

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.

Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, Introna M.

Blood. 2013 Nov 14;122(20):3482-91. doi: 10.1182/blood-2013-05-504043. Epub 2013 Oct 8.

19.

Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms.

Introna M, Golay J, Rambaldi A.

Immunol Lett. 2013 Sep-Oct;155(1-2):27-30. doi: 10.1016/j.imlet.2013.09.017. Epub 2013 Sep 29. Review.

PMID:
24084446
20.

Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics.

Golay J, Semenzato G, Rambaldi A, Foà R, Gaidano G, Gamba E, Pane F, Pinto A, Specchia G, Zaja F, Regazzi M.

MAbs. 2013 Nov-Dec;5(6):826-37. doi: 10.4161/mabs.26008. Epub 2013 Aug 8. Review.

21.

The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia.

Casolaro A, Golay J, Albanese C, Ceruti R, Patton V, Cribioli S, Pezzoni A, Losa M, Texido G, Giussani U, Marchesi F, Amboldi N, Valsasina B, Bungaro S, Cazzaniga G, Rambaldi A, Introna M, Pesenti E, Alzani R.

PLoS One. 2013;8(3):e58424. doi: 10.1371/journal.pone.0058424. Epub 2013 Mar 8.

22.

Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.

Bologna L, Gotti E, Da Roit F, Intermesoli T, Rambaldi A, Introna M, Golay J.

J Immunol. 2013 Jan 1;190(1):231-9. doi: 10.4049/jimmunol.1202645. Epub 2012 Dec 5.

23.

Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients.

Amaru Calzada A, Pedrini O, Finazzi G, Leoni F, Mascagni P, Introna M, Rambaldi A, Golay J; Associazione Italiana per la Ricerca sul Cancro-Gruppo Italiano Malattie Mieloproliferative Investigators.

Exp Hematol. 2013 Mar;41(3):253-60.e2. doi: 10.1016/j.exphem.2012.10.013. Epub 2012 Oct 27.

PMID:
23111067
24.

The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.

Amaru Calzada A, Todoerti K, Donadoni L, Pellicioli A, Tuana G, Gatta R, Neri A, Finazzi G, Mantovani R, Rambaldi A, Introna M, Lombardi L, Golay J; AGIMM Investigators.

Exp Hematol. 2012 Aug;40(8):634-45.e10. doi: 10.1016/j.exphem.2012.04.007. Epub 2012 May 8.

PMID:
22579713
25.

Lepidopteran cells, an alternative for the production of recombinant antibodies?

Cérutti M, Golay J.

MAbs. 2012 May-Jun;4(3):294-309. doi: 10.4161/mabs.19942. Epub 2012 Apr 26. Review.

26.

Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays.

Golay J, Introna M.

Arch Biochem Biophys. 2012 Oct 15;526(2):146-53. doi: 10.1016/j.abb.2012.02.011. Epub 2012 Feb 25. Review.

PMID:
22387378
27.

Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring.

Dander E, Lucchini G, Vinci P, Introna M, Masciocchi F, Perseghin P, Balduzzi A, Bonanomi S, Longoni D, Gaipa G, Belotti D, Parma M, Algarotti A, Capelli C, Golay J, Rovelli A, Rambaldi A, Biondi A, Biagi E, D'Amico G.

Leukemia. 2012 Jul;26(7):1681-4. doi: 10.1038/leu.2011.384. Epub 2012 Jan 13. No abstract available.

PMID:
22289986
28.

Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action.

Salvi M, Vannucchi G, Currò N, Introna M, Rossi S, Bonara P, Covelli D, Dazzi D, Guastella C, Pignataro L, Ratiglia R, Golay J, Beck-Peccoz P.

Arch Ophthalmol. 2012 Jan;130(1):122-4. doi: 10.1001/archopthalmol.2011.1215. No abstract available.

PMID:
22232486
29.

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.

Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, Leusen JH.

Haematologica. 2011 Dec;96(12):1822-30. doi: 10.3324/haematol.2011.047159. Epub 2011 Aug 31.

30.

Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.

Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, Introna M.

Blood. 2011 Sep 22;118(12):3301-10. doi: 10.1182/blood-2011-02-336321. Epub 2011 Aug 5.

31.

Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.

Loisel S, André PA, Golay J, Buchegger F, Kadouche J, Cérutti M, Bologna L, Kosinski M, Viertl D, Delaloye AB, Berthou C, Mach JP, Boumsell L.

Mol Cancer. 2011 Apr 19;10:42. doi: 10.1186/1476-4598-10-42.

32.

Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate.

Capelli C, Gotti E, Morigi M, Rota C, Weng L, Dazzi F, Spinelli O, Cazzaniga G, Trezzi R, Gianatti A, Rambaldi A, Golay J, Introna M.

Cytotherapy. 2011 Aug;13(7):786-801. doi: 10.3109/14653249.2011.563294. Epub 2011 Mar 18.

PMID:
21417678
33.

Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.

Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, Golay J.

J Immunol. 2011 Mar 15;186(6):3762-9. doi: 10.4049/jimmunol.1000303. Epub 2011 Feb 4.

34.

Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies.

Pievani A, Belussi C, Klein C, Rambaldi A, Golay J, Introna M.

Blood. 2011 Jan 13;117(2):510-8. doi: 10.1182/blood-2010-06-290858. Epub 2010 Nov 3.

35.

Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death.

Golay J, Bologna L, André PA, Buchegger F, Mach JP, Boumsell L, Introna M.

Blood. 2010 Oct 28;116(17):3372-3; author reply 3373-4. doi: 10.1182/blood-2010-06-289736. No abstract available.

36.

Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility.

Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA, Capelli C, Rambaldi A, Cassis P, Rizzo P, Cortinovis M, Marasà M, Golay J, Noris M, Remuzzi G.

Clin J Am Soc Nephrol. 2011 Feb;6(2):412-22. doi: 10.2215/CJN.04950610. Epub 2010 Oct 7.

37.

Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation.

Introna M, Pievani A, Borleri G, Capelli C, Algarotti A, Micò C, Grassi A, Oldani E, Golay J, Rambaldi A.

Biol Blood Marrow Transplant. 2010 Nov;16(11):1603-7. doi: 10.1016/j.bbmt.2010.05.015. Epub 2010 Jun 1.

38.

Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population.

Lucchini G, Introna M, Dander E, Rovelli A, Balduzzi A, Bonanomi S, Salvadè A, Capelli C, Belotti D, Gaipa G, Perseghin P, Vinci P, Lanino E, Chiusolo P, Orofino MG, Marktel S, Golay J, Rambaldi A, Biondi A, D'Amico G, Biagi E.

Biol Blood Marrow Transplant. 2010 Sep;16(9):1293-301. doi: 10.1016/j.bbmt.2010.03.017. Epub 2010 Mar 27.

39.

Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models.

Alzani R, Pedrini O, Albanese C, Ceruti R, Casolaro A, Patton V, Colotta F, Rambaldi A, Introna M, Pesenti E, Ciomei M, Golay J.

Exp Hematol. 2010 Apr;38(4):259-269.e2. doi: 10.1016/j.exphem.2010.02.004. Epub 2010 Feb 16.

PMID:
20167248
40.

Complement in antibody therapy: friend or foe?

Introna M, Golay J.

Blood. 2009 Dec 17;114(26):5247-8. doi: 10.1182/blood-2009-10-249532. No abstract available.

41.

Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b.

Todoerti K, Barbui V, Pedrini O, Lionetti M, Fossati G, Mascagni P, Rambaldi A, Neri A, Introna M, Lombardi L, Golay J.

Haematologica. 2010 Feb;95(2):260-9. doi: 10.3324/haematol.2009.012088. Epub 2009 Aug 27.

42.

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma.

Galli M, Salmoiraghi S, Golay J, Gozzini A, Crippa C, Pescosta N, Rambaldi A.

Ann Hematol. 2010 Feb;89(2):185-90. doi: 10.1007/s00277-009-0793-8. Epub 2009 Jul 25.

PMID:
19633847
43.

The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs.

Capelli C, Salvade A, Pedrini O, Barbui V, Gotti E, Borleri G, Cabiati B, Belotti D, Perseghin P, Bellavita P, Biondi A, Biagi E, Rambaldi A, Golay J, Introna M.

Cytotherapy. 2009;11(4):403-13. doi: 10.1080/14653240902960437.

PMID:
19462317
44.

Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.

Franceschetti M, Pievani A, Borleri G, Vago L, Fleischhauer K, Golay J, Introna M.

Exp Hematol. 2009 May;37(5):616-628.e2. doi: 10.1016/j.exphem.2009.01.010.

PMID:
19375652
45.

M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.

Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli M, Palumbo GA, Introna M, Golay J.

J Immunol. 2009 Apr 1;182(7):4415-22. doi: 10.4049/jimmunol.0713732.

46.

Chemokines and antagonists in non-Hodgkin's lymphoma.

Golay J, Introna M.

Expert Opin Ther Targets. 2008 May;12(5):621-35. doi: 10.1517/14728222.12.5.621 . Review.

PMID:
18410244
47.

The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).

Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, Carobbio A, Introna M, Barbui T, Golay J, Rambaldi A.

Leukemia. 2008 Apr;22(4):740-7. Epub 2007 Dec 13.

PMID:
18079739
48.

Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts.

Capelli C, Domenghini M, Borleri G, Bellavita P, Poma R, Carobbio A, Micò C, Rambaldi A, Golay J, Introna M.

Bone Marrow Transplant. 2007 Oct;40(8):785-91. Epub 2007 Aug 6.

PMID:
17680021
49.

FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.

Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, Golay J, Pulsoni A, Foà R, Rambaldi A.

Haematologica. 2007 Aug;92(8):1127-30.

50.

The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.

Golay J, Cuppini L, Leoni F, Micò C, Barbui V, Domenghini M, Lombardi L, Neri A, Barbui AM, Salvi A, Pozzi P, Porro G, Pagani P, Fossati G, Mascagni P, Introna M, Rambaldi A.

Leukemia. 2007 Sep;21(9):1892-900. Epub 2007 Jul 19.

PMID:
17637810

Supplemental Content

Support Center